# Colgate-Palmolive Company (CL) — Narrative, Q3 2026 Amounts are in US dollars. Colgate-Palmolive reports on a calendar fiscal year; its most recent annual report covers the fiscal year ended December 31, 2025, and the latest quarterly report covers the quarter ended September 30, 2026. ## Business *From the FY2025 Form 10-K, accession 0000021665-26-000006.* Colgate-Palmolive sells everyday consumer staples — toothpaste, toothbrushes, mouthwash, soaps, shower gels, deodorants, skin care, dishwashing liquids, household cleaners, fabric conditioners — and specialty pet food, in more than 200 countries and territories. In 2025, Oral Care made up 44% of worldwide net sales, Personal Care 17%, Home Care 16% and Hill's Pet Nutrition 23%. About two-thirds of net sales come from outside the United States, and roughly 45% from emerging markets. Its customers are retailers, wholesalers and distributors; Pet Nutrition goes through authorized pet supply retailers, veterinarians and eCommerce. Walmart and its affiliates bought about 11% of 2025 net sales, and no other customer reached 10%. It reports two product segments: - **Oral, Personal and Home Care.** Colgate leads the world in toothpaste (41.3% global share for full-year 2025) and manual toothbrushes (32.4%), and it leads in liquid hand soap. Its brands include Colgate, Darlie, elmex, hello, meridol, Sorriso and Tom's of Maine in oral care; Palmolive, Protex, Softsoap, Irish Spring, Sanex, Speed Stick and Lady Speed Stick in personal care; EltaMD, Filorga and PCA SKIN in skin health; and Ajax, Axion, Fabuloso, Murphy, Suavitel and Soupline in home care. Oral Care also sells pharmaceutical products to dentists and other oral health professionals. Oral Care is a substantial part of the Asia Pacific business. - **Hill's Pet Nutrition.** This segment sells specialty dog and cat food in over 80 countries under Hill's Science Diet (everyday nutrition, sold as Science Plan in Europe), Hill's Prescription Diet (therapeutic foods) and Prime100, a fresh pet food brand in Australia. Prime100 came with the April 30, 2025 purchase of Care TopCo Pty Ltd for AU$471 million (about $301 million). The consumer products segment is run through regional reportable operating segments. In the 10-K there were five: North America, Latin America, Europe, Asia Pacific and Africa/Eurasia. **The structure changed for 2026.** Starting with the quarter ended March 31, 2026, Europe and Africa/Eurasia (excluding Russia and Belarus) were combined with the skin health business, which had been in North America, to form a new Europe, Middle East & Africa (EMEA) segment. Russia and Belarus moved into Asia Pacific. That leaves four regional segments — North America, Latin America, EMEA and Asia Pacific — alongside Hill's Pet Nutrition. The company recast its historical segment information onto the new basis in a Form 8-K filed March 17, 2026 (accession 0000021665-26-000010). Consolidated results did not change. Corporate costs sit outside the segments: overhead, research and development ($366 million in 2025), stock-based compensation, restructuring charges and gains or losses on sales of non-core product lines. At year-end 2025 the company had about 33,600 employees in more than 100 countries, over 84% of them outside the United States. It operates about 325 owned or leased properties. Its main research and development centers are in New Jersey (oral and personal care), Mexico (home care) and Kansas (pet nutrition), and it runs shared service centers in India, Mexico and Poland. **Strategy.** The company finished its 2025 strategic plan and now runs a 2030 strategy built on five priorities: using the reach of its brands, science-based innovation, "omni-channel demand generation" across retail, eCommerce and social media, data, analytics and AI capabilities, and its internal culture. Two cost programs pay for it. One is an ongoing "funding-the-growth" program that cuts material, logistics and overhead costs. The other is the Strategic Growth and Productivity Program, approved July 31, 2025, which realigns the organization and supply chain. When the 10-K was filed, that program was expected to cost $200 to $300 million pre-tax in total. It was expanded in April 2026 (see Current quarter). ## Risk factors *From the FY2025 Form 10-K, accession 0000021665-26-000006. The Q3 2026 Form 10-Q (accession 0000021665-26-000048) reports no material changes to these risk factors.* - **International exposure and currency.** About two-thirds of sales originate outside the US. That exposes Colgate to exchange-rate swings, which shrink the dollar value of foreign profits and raise local supply costs. It also exposes the company to exchange controls, limits on getting cash home, price and profit controls, and possible expropriation. Hyper-inflationary economies, including Argentina, Nigeria and Türkiye, make currency volatility worse. Colgate offsets this with price increases, sourcing and selective hedging, and it warns these measures have not always been enough. - **Geopolitics, wars and trade.** Russia and Ukraine: Eurasia was about 1% of 2025 net sales and about 2% of operating profit. Colgate has no factories in Russia but has trouble getting cash out of the country and finding banking services there. Venezuela: the company still has a factory there, but local results have been excluded from the consolidated statements since December 31, 2015. US tariffs following the 2025 executive orders, retaliation by trading partners, and renegotiation of the USMCA have added to input costs and hurt consumer sentiment. The 10-Q adds a further risk: the Middle East conflict, including between the United States and Iran, has raised shipping costs and the prices of oil, resin and agricultural inputs. - **Input-cost volatility.** Resins, essential and tropical oils, pulp, tallow, corn, poultry and soybeans are all subject to price swings. In 2025, higher raw and packaging material costs cut 420 basis points from gross margin. Price increases used to offset costs can reduce volume or push shoppers to private label, and Colgate hedges commodities only to a limited extent. - **Competition and a shifting retail landscape.** Colgate competes with multinationals, local players, private label and new direct-to-consumer entrants that eCommerce, social commerce and AI have made easier. Large retailers have more bargaining power and exclusive first-party consumer data. They demand trade discounts, slotting fees, retail media spending and changes to assortment. Retailers consolidating would concentrate the risk further. - **Innovation and reputation.** Growth depends on launching differentiated products and getting regulatory approvals, including from the FDA. Negative publicity about ingredients, packaging, sourcing or AI-generated content on social media could damage the brands, and counterfeits are a further brand threat. - **Acquisitions, divestitures and impairment.** Acquired businesses can disappoint. In Q4 2025 the skin health business, mainly Filorga, triggered a non-cash charge of $794 million after tax ($919 million pre-tax) after weaker category growth and performance, particularly in China. - **Supply chain and shared-service concentration.** Some materials come from single or few suppliers. Finance, IT, customer service and logistics are concentrated in a handful of key office facilities. - **Cost programs may under-deliver.** Funding-the-growth savings and the Strategic Growth and Productivity Program may come in late or short of plan. Parts of the restructuring require negotiation with works councils and unions. - **Cybersecurity and IT.** Colgate depends on internal and third-party IT/OT systems, including cloud providers. The company has had cyber and data incidents, none with a material impact so far. The 10-Q notes an enterprise IT upgrade and move to the cloud now under way. - **Regulation of ingredients.** Regulators are increasingly reviewing fluoride, titanium dioxide, synthetic colors and PFAS. Restrictions could force reformulation and hurt reputation. Anti-bribery, sanctions and trade-control rules also apply across a large international footprint. - **Litigation, especially talc.** Colgate is a defendant in suits alleging that its historic talcum powder products contained asbestos or caused cancer. The 10-K describes talc litigation outcomes across the industry as ranging from dismissals to outsized compensatory and punitive jury awards (see Current quarter for the case count). - **Macro, credit and tax.** Economic downturns push consumers toward cheaper products, and disruptions in the credit markets or a rating change could raise funding costs. On tax, the OECD Pillar II minimum tax and the January 2026 "Side-by-Side Package" are still being worked through. The IRS has also proposed imputing income on activities of one international operation. The 10-K puts the tax plus interest at about $165 million for 2010–2018; the 10-Q puts it at about $170 million for 2010–2021. Colgate believes the assessment is without merit, and the amount is not included in its uncertain tax positions. ## Management's discussion — fiscal 2025 *From the FY2025 Form 10-K, accession 0000021665-26-000006, with recast segment data from the Form 8-K filed March 17, 2026, accession 0000021665-26-000010.* **Headline results.** Net sales rose 1.4% to $20,382 million. Net selling prices added 2.1%, volume subtracted 0.4% and foreign exchange 0.3%; the Prime100 acquisition added 0.3% to volume. Organic sales, which exclude currency, acquisitions and divestments (a non-GAAP measure), also grew 1.4%. Hill's results were held back by lower private label pet food sales, which cut 320 basis points from that segment's organic growth. In its Q4 2025 earnings release (Form 8-K, accession 0000021665-26-000003), Colgate said it is exiting the private label pet food business. **Margins.** Gross margin slipped to 60.1% from 60.5% (60.6% excluding 2024 restructuring charges). Material costs took off 420 basis points, partly offset by funding-the-growth savings (260 bps), pricing (80 bps) and mix (30 bps). Advertising was $2,703 million, 13.3% of sales. GAAP operating profit fell 23% to $3,306 million because of the $919 million pre-tax skin health impairment, a $99 million ERISA litigation charge, restructuring and acquisition costs. Excluding those items, operating profit was essentially flat at $4,347 million against $4,353 million, with margin down 40 bps to 21.3%. The impairment wrote down the Filorga trademark by $244 million and customer relationships by $93 million, and took a $582 million goodwill charge that left $51 million of skin health goodwill. **Earnings.** GAAP net income attributable to Colgate fell to $2,132 million, or $2.63 per diluted share, from $2,889 million ($3.51). The effective tax rate was 26.1%. Excluding the items above, net income rose 1% to $2,996 million and diluted EPS rose 3% to $3.69 from $3.60. **Segments, as filed in the 10-K (old five-region basis):** - North America: net sales down 1.6% to $4,045 million; organic sales down 1.6% on weaker skin health, body wash, underarm protection and hand dish. Operating profit down 7% to $784 million. - Latin America: net sales down 0.1% to $4,776 million after 4.0% negative currency; organic up 3.9%, led by Mexico, Argentina and Brazil. Operating profit down 8% to $1,411 million as material costs cut gross margin by 760 bps. - Europe: net sales up 6.9% to $2,962 million; organic up 2.6%. Operating profit up 14% to $748 million. - Asia Pacific: net sales down 1.5% to $2,814 million; organic down 1.0% on Greater China and India. Operating profit down 6% to $760 million. - Africa/Eurasia: net sales up 7.0% to $1,172 million; organic up 6.5%, led by Türkiye and North Africa/Middle East. Operating profit up 1% to $255 million. - Hill's Pet Nutrition: net sales up 2.9% to $4,613 million; organic up 1.2%. Operating profit up 10% to $1,064 million, with margin up 160 bps to 23.1%. **The same 2025 year on the new four-region basis.** The March 2026 recast gives: - North America: $3,679 million net sales and $790 million operating profit. - Latin America: $4,776 million and $1,411 million. - EMEA: $4,276 million and $938 million. - Asia Pacific: $3,038 million and $820 million. Hill's and the Corporate line ($1,717 million loss) are unchanged. 2026 segment figures should be compared with these recast amounts, not with the 10-K segment table above. **Cash and capital.** Operating cash flow rose 2% to a record $4,198 million, and capital expenditures were $564 million. Dividends paid totalled $1,823 million ($2.06 per share), and share repurchases cost $1,210 million. Total debt was $7,988 million and cash $1,288 million at year-end. In 2025 the company issued $500 million of 4.20% five-year notes in April and €600 million of 3.25% ten-year notes in November. A $5 billion buyback authorization (the "2025 Program") replaced the prior program in March 2025. The $3 billion revolving credit facility now runs to November 2030. ## Current quarter — Q3 2026 *From the Q3 2026 Form 10-Q, accession 0000021665-26-000048, and the earnings release furnished on Form 8-K, accession 0000021665-26-000047 (both October 30, 2026). Q1 and Q2 2026 organic growth rates come from the earnings releases on Form 8-K, accessions 0000021665-26-000022 (May 1) and 0000021665-26-000041 (July 31). Segment figures are on the new four-region basis, with 2025 comparisons recast.* **Growth picked up in Q3.** Net sales rose 4.6% to $5,369 million on 1.7% volume growth, 2.0% net pricing and a 1.0% currency benefit. Organic sales grew 3.6%, faster than the 2.9% in Q1 and 2.4% in Q2 2026. The figure includes a 20 bp drag from the shrinking private label pet food business. Management described Q3 as its fourth straight quarter of sequential improvement in worldwide volume growth. Year to date, toothpaste share was 41.4% (up 0.3 points) and manual toothbrush share 33.1% (up 0.8 points). **Margin and reinvestment.** Gross margin rose 80 bps to 60.2% (60.3% excluding restructuring). Funding-the-growth savings (290 bps), pricing (80 bps) and mix (20 bps) more than covered material cost inflation of 300 bps. Advertising absorbed most of that gain, rising 15% to $775 million, or 14.4% of sales against 13.1%. Excluding restructuring, operating profit rose 5% to $1,117 million, but margin improved only 20 bps to 20.8%. On a GAAP basis, which includes $30 million of pre-tax restructuring charges, operating profit grew 3% to $1,088 million while margin dipped 30 bps to 20.3%. Diluted EPS was $0.94 against $0.91. Excluding restructuring it was $0.97, up 7%. **Q3 by segment** (net sales; organic growth; operating profit): - North America: $905 million, down 1.7%; organic down 1.6%, driven by the United States, with declines in body wash, underarm protection and toothpaste. Operating profit fell 11% to $177 million, and margin fell 210 bps to 19.5%. Higher SG&A, mostly advertising, took 160 bps, and lower gross margin took 70 bps; within gross margin, material costs rose 520 bps against 350 bps of savings. - Latin America: $1,326 million, up 12.5% including 6.5% currency; organic up 6.0%, led by Brazil, Argentina and Colombia. Operating profit rose 17% to $392 million. - EMEA: $1,130 million, up 1.4%; organic up 2.7%, led by Türkiye, the United Kingdom and Spain and partly offset by the Middle East region. Operating profit rose 8% to $262 million. - Asia Pacific: $802 million, up 3.5%; organic up 4.6%, led by India, Greater China and the Philippines. Operating profit slipped 1% to $211 million, and margin fell 110 bps to 26.4%. Higher advertising was one cause; the other was material costs, up 550 bps and only partly offset by 380 bps of savings. - Hill's Pet Nutrition: $1,205 million, up 5.6%; organic up 5.7%, net of a 70 bp private label drag, on growth in therapeutic and wellness foods. Operating profit rose 5% to $267 million, but margin fell 20 bps to 22.2%. Higher SG&A, driven by a 290 bp rise in advertising as a share of sales, outweighed a 170 bp gross profit gain. **Nine months.** Net sales rose 6.0% to $16,055 million, and organic sales grew 3.0%. GAAP operating profit fell 5% to $3,069 million. It absorbed $327 million of restructuring charges, out of $333 million pre-tax for the period, with $300 million recorded in other expense. Excluding those charges, and the ERISA and acquisition costs in the 2025 period, operating profit rose to $3,396 million from $3,240 million. GAAP diluted EPS was $2.61 against $2.67. Excluding the items, EPS rose 7% to $2.94. Management estimates a full-year effective tax rate of 23.5% before discrete items. **Restructuring expanded.** On April 30, 2026 the Board expanded the Strategic Growth and Productivity Program. Expected total pre-tax charges rose to $350–$550 million from $200–$300 million. Annualized pre-tax savings are projected at $200–$300 million, and substantially all charges are expected by December 31, 2028. About 70–80% of the charges are employee-related, and EMEA accounts for the largest share (25–30%). Cumulative charges reached $346 million pre-tax ($278 million after tax) by September 30, 2026, and the restructuring accrual stood at $172 million. **Cash, debt and capital return.** Operating cash flow for the nine months rose 6% to $2,913 million, and capital expenditures were $400 million. Capex is planned at about 3.0% of 2026 net sales. In Q1 2026 Colgate repaid at maturity $500 million of 4.800% notes and €500 million of 0.500% notes, funding both with commercial paper. Commercial paper rose to $1,037 million from $147 million at year-end, while total debt fell to $7,716 million from $7,988 million. Cash was $1,527 million, of which $1,515 million was held abroad. Dividends paid in the nine months were $1,308 million; the quarterly dividend rose to $0.53 from $0.52 starting in Q2. Share repurchases cost $927 million. In Q3 alone the company bought about 3.68 million shares at an average $89.70, leaving about $3,228 million under the 2025 Program. **Full-year 2026 guidance (October 30, 2026, at spot rates).** The company raised its margin and Base Business EPS outlook and narrowed the sales range: - Net sales up 4% to 5% (previously 2% to 6%), including a low-single-digit currency benefit. - Organic sales growth broadly in line with the nine-month rate (previously 1% to 4%), including the effect of exiting private label pet food. - Gross margin up on both a GAAP and Base Business basis (previously roughly flat). Advertising up in dollars and as a percentage of sales. - GAAP EPS up by a double-digit percentage. - Base Business EPS up 5% to 7% (previously mid-single digits). **Outlook risks management flags.** Management expects category softness to last through the rest of 2026. It also expects continued pressure from tariffs and USMCA renegotiation, the Ukraine war, and the Middle East conflict's effect on oil, resin and freight costs. In management's view, consumers may trade down or switch to private label. **Litigation update.** - Talc: 561 individual cases were pending at September 30, 2026, against 525 at June 30. In the nine months, 236 new cases were filed and 128 resolved, and settlements were not material. The 10-K had reported 454 pending cases at December 31, 2025, up from 308 a year earlier; the 10-Q gives the year-end figure as 453. - ERISA: the pension lawsuit was settled for $332 million, inclusive of fees. The court granted final approval in January 2026, and the $99 million of plaintiffs' attorneys' fees has been paid by the company. - Overall exposure: Colgate estimates reasonably possible losses above accruals at $0 to about $225 million across disclosed matters. ## Subsequent events *From the Q3 2026 Form 10-Q, accession 0000021665-26-000048, and Form 8-K accession 0000021665-26-000047.* The Q3 2026 10-Q has no separate subsequent-events note. It reports no acquisitions, divestitures, debt issuances or other financings after September 30, 2026. Post-quarter developments in the filings: - **Brazilian tax litigation (October 2026).** This case stems from Colgate's 1995 purchase of the Kolynos oral care business. In December 2025, the Brazilian Federal Court of Appeals ruled against the company on deducting corporate income tax for 1999–2001, a case worth about $19 million. Colgate's further appeals were denied in August and again in October 2026, and it has appealed again. The disputed interest-deduction assessments that include this case total about $107 million at current exchange rates. Colgate believes it is more likely than not to prevail. - **Guidance raised (October 30, 2026).** The Q3 earnings release raised full-year 2026 guidance, as detailed above.